Skip to main content
    E

    Evotec SE ADR (EVO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.56
    -0.02 (-1.27%)

    Market Cap: $561.51M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Evotec SE ADR (EVO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in EUR.

    Evotec SE ADR reported revenue of EUR 757.26M for the fiscal year ended Dec 31, 2025, down 5.0% from the year before. That year, net income was EUR -99.43M with a net margin of -13.1%, operating cash flow was EUR -9.06M and free cash flow was EUR -78.74M. The quarter ended Sep 30, 2026 had revenue of EUR 164.93M and net income of EUR -26.74M.

    Revenue and Margins

    The operating margin was -17.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from EUR 164.51M, a compound annual rate of 18.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025757.26M-5.0%8.3%-17.9%-13.1%
    Dec 2024796.97M+2.0%14.4%-17.9%-24.6%
    Dec 2023781.43M+4.0%22.4%-13.7%-10.7%
    Dec 2022751.45M+21.6%23.2%2.8%-23.4%
    Dec 2021618.03M+23.4%24.5%6.6%34.9%
    Dec 2020500.92M+12.2%25.1%9.7%1.3%
    Dec 2019446.44M+18.9%29.8%14.0%8.5%
    Dec 2018375.40M+45.7%29.8%20.6%22.4%
    Dec 2017257.63M+56.6%32.0%14.6%9.4%
    Dec 2016164.51MN/A35.6%19.1%16.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue757.26M796.97M781.43M751.45M618.03M500.92M446.44M375.40M257.63M164.51M
    Cost of revenue694.60M682.09M606.38M577.38M466.49M375.18M313.55M263.39M175.06M105.95M
    Gross profit62.66M114.88M175.05M174.06M151.54M125.74M132.89M112.02M82.57M58.55M
    Research and development74.33M50.86M112.53M76.64M65.70M59.61M58.43M35.62M17.61M18.11M
    Operating income-135.31M-142.52M-107.09M20.85M41.00M48.56M62.59M77.46M37.49M31.34M
    Net income-99.43M-196.08M-83.91M-175.66M215.51M6.28M38.16M84.17M24.26M27.53M
    EBITDA-13.89M-80.66M-7.16MN/A316.63M90.36M86.77M105.88MN/A45.57M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue164.93M145.85M159.22M253.27M163.89M171.24M199.98M221.23M184.89M182.12M208.73M201.31M
    Gross profit19.80M-1.61M-1.59M78.46M-62.00K8.59M27.23M46.10M18.28M15.74M34.76M37.67M
    Operating income-27.11M-51.97M-56.35M37.21M-44.50M-27.77M-20.01M8.13M-26.49M-104.61M-18.21M-11.55M
    Net income-26.74M-47.42M-123.94M14.62M-43.09M-43.48M-31.58M-40.84M-39.63M-94.93M-20.67M-16.13M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of EUR 447.64M exceeded cash and equivalents by 29.31M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets1.78B1.91B2.30B2.26B2.24B1.84B1.38B771.88M667.27M351.37M
    Current assets762.62M681.96M903.16M1.07B1.10B806.13M527.05M249.77M180.25M169.24M
    Cash and equivalents418.34M306.39M510.91M400.70M699.33M517.05M310.97M109.06M67.02M83.94M
    Total liabilities964.64M959.98M1.18B1.07B857.48M951.26M844.39M347.00M335.52M137.43M
    Short-term debt103.64M50.80M149.09M16.38M50.61M36.72M23.27M56.92M168.47M21.60M
    Long-term debt344.01M392.74M307.09M328.30M326.34M331.02M324.89M54.68M20.30MN/A
    Shareholder equity813.36M952.52M1.12B1.19B1.38B886.41M535.47M424.00M330.75M213.03M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets1.50B1.57B1.64B1.71B1.77B2.12B2.10B1.91B2.22B2.14B2.39B2.25B
    Total liabilities863.31M908.40M941.17M900.24M972.56M1.13B1.12B959.98M1.14B1.06B1.19B1.13B
    Cash and equivalents299.01M348.36M388.32M401.79M174.04M314.39M308.26M293.46M258.14M237.80M462.58M510.91M
    Shareholder equity641.66M665.58M700.35M813.70M800.14M992.83M985.29M952.52M1.08B1.08B1.20B1.12B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-9.06M18.22M33.95M205.81M122.24M44.72M42.22M156.24M10.83M67.36M
    Capital expenditures69.68M132.24M216.00M181.35M118.94M99.07M31.91M27.87M17.59M10.15M
    Free cash flow-78.74M-114.02M-182.05M24.46M3.29M-54.35M10.31M128.37M-6.76M57.21M
    Dividends paid00000N/AN/AN/A1.72M2.02M
    Investing cash flow159.86M-71.19MN/A-412.80M-243.85M-155.09M-86.63M-39.13M-269.03M-5.97M
    Financing cash flow-30.93M-161.42M84.82M-58.15M398.43M246.41M211.26M-77.76M240.72M-19.67M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-43.91M-110.23M-2.18M63.63M-67.56M26.56M-31.81M74.22M42.60M-56.51M-51.22M19.94M
    Capital expenditures8.01M9.32M4.23M15.52M21.40M23.86M21.84M25.08M28.34M42.28M43.67M63.37M
    Free cash flow-51.92M-119.54M-6.41M48.11M-88.96M2.70M-53.65M49.14M14.26M-98.79M-94.89M-43.42M
    Last 12 quarters

    Frequently Asked Questions About EVO

    What is Evotec SE ADR's annual revenue?

    Evotec SE ADR reported revenue of EUR 757.26M for the fiscal year ended Dec 31, 2025.

    How fast is Evotec SE ADR's revenue growing?

    Revenue was down 5.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.3%.

    Is Evotec SE ADR profitable?

    No. Evotec SE ADR reported net income of EUR -99.43M for the fiscal year ended Dec 31, 2025, with a net margin of -13.1%.

    How much free cash flow does EVO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -9.06M minus capital expenditures of EUR 69.68M produced free cash flow of EUR -78.74M.

    How much debt does Evotec SE ADR have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 344.01M, short-term debt of EUR 103.64M and cash and equivalents of EUR 418.34M.